{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:28:19Z","timestamp":1793500099544,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-01016-6","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T16:33:38Z","timestamp":1731342818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9762-5001","authenticated-orcid":false,"given":"Kun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minrun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-1327","authenticated-orcid":false,"given":"Lianpai","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-615X","authenticated-orcid":false,"given":"George F.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"1016_CR1","doi-asserted-by":"crossref","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 KP.2 variant. Lancet Infect. Dis. 24, e416 (2024).","DOI":"10.1016\/S1473-3099(24)00298-6"},{"key":"1016_CR2","doi-asserted-by":"crossref","unstructured":"Liu, C. et al. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity. Cell Rep. Med. 5, 101553 (2024).","DOI":"10.1016\/j.xcrm.2024.101553"},{"key":"1016_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi, N. et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA 326, 35\u201345 (2021).","journal-title":"JAMA"},{"key":"1016_CR4","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","volume":"386","author":"L Dai","year":"2022","unstructured":"Dai, L. et al. Efficacy and safety of the RBD-dimer-based COVID-19 vaccine ZF2001 in adults. N. Engl. J. Med. 386, 2097\u20132111 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/intimm\/dxac031","volume":"34","author":"K Xu","year":"2022","unstructured":"Xu, K., Fan, C., Han, Y., Dai, L. & Gao, G. F. Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. Int. Immunol. 34, 595\u2013607 (2022).","journal-title":"Int. Immunol."},{"key":"1016_CR6","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S0140-6736(23)00129-0","volume":"401","author":"Y Pan","year":"2023","unstructured":"Pan, Y. et al. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. Lancet 401, 664\u2013672 (2023).","journal-title":"Lancet"},{"key":"1016_CR7","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s44318-024-00062-z","volume":"43","author":"W Li","year":"2024","unstructured":"Li, W. et al. Key mechanistic features of the trade-off between antibody escape and host cell binding in the SARS-CoV-2 Omicron variant spike proteins. EMBO J. 43, 1484\u20131498 (2024).","journal-title":"EMBO J."},{"key":"1016_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.medj.2024.03.006","volume":"5","author":"Q He","year":"2024","unstructured":"He, Q. et al. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies. Med 5, 401\u2013413.e404 (2024).","journal-title":"Med"},{"key":"1016_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114520","volume":"43","author":"P Li","year":"2024","unstructured":"Li, P. et al. Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants. Cell Rep. 43, 114520 (2024).","journal-title":"Cell Rep."},{"key":"1016_CR10","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1016\/S1473-3099(24)00415-8","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants. Lancet Infect. Dis. 24, e482\u2013e483 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1016_CR11","doi-asserted-by":"crossref","unstructured":"Yaugel-Novoa, M. et al. Prior COVID-19 immunization does not cause IgA- or IgG-dependent enhancement of SARS-CoV-2 infection. Vaccines 11, 773 (2023).","DOI":"10.3390\/vaccines11040773"},{"key":"1016_CR12","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1016\/j.cell.2021.06.021","volume":"184","author":"D Li","year":"2021","unstructured":"Li, D. et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 184, 4203\u20134219.e4232 (2021).","journal-title":"Cell"},{"key":"1016_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07735-2","volume":"22","author":"L Gan","year":"2022","unstructured":"Gan, L., Chen, Y., Tan, J., Wang, X. & Zhang, D. Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis. BMC Infect. Dis. 22, 742 (2022).","journal-title":"BMC Infect. Dis."},{"key":"1016_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326 (2022).","journal-title":"Immunol. Rev."},{"key":"1016_CR15","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1080\/22221751.2021.1913973","volume":"10","author":"A Rockstroh","year":"2021","unstructured":"Rockstroh, A. et al. Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort. Emerg. Microbes Infect. 10, 774\u2013781 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"1016_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00630-0","volume":"8","author":"D Benkeser","year":"2023","unstructured":"Benkeser, D. et al. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. NPJ Vaccines 8, 36 (2023).","journal-title":"NPJ Vaccines"},{"key":"1016_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.15585\/mmwr.mm7337e2","volume":"73","author":"L Panagiotakopoulos","year":"2024","unstructured":"Panagiotakopoulos, L. et al. Use of COVID-19 vaccines for persons aged \u22656 months: recommendations of the advisory committee on immunization practices\u2014United States, 2024\u20132025. MMWR Morb. Mortal. Wkly Rep. 73, 819\u2013824 (2024).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1016_CR18","doi-asserted-by":"publisher","unstructured":"COVID-19 update: new Pfizer and Moderna vaccine formulations for 2024\u20132025. Med. Lett. Drugs Ther. 66, 151\u2013152. https:\/\/doi.org\/10.58347\/tml.2024.1711c (2024).","DOI":"10.58347\/tml.2024.1711c"},{"key":"1016_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2107715","volume":"385","author":"A Jara","year":"2021","unstructured":"Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 385, 875\u2013884 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai, L. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182, 722\u2013733.e711 (2020).","journal-title":"Cell"},{"key":"1016_CR21","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.cell.2022.04.029","volume":"185","author":"K Xu","year":"2022","unstructured":"Xu, K. et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 185, 2265\u20132278.e2214 (2022).","journal-title":"Cell"},{"key":"1016_CR22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1056\/NEJMc2216233","volume":"388","author":"D Li","year":"2023","unstructured":"Li, D. et al. Neutralization of BQ.1, BQ.1.1, and XBB with RBD-dimer vaccines. N. Engl. J. Med. 388, 1142\u20131145 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR23","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMc2119426","volume":"386","author":"X Zhao","year":"2022","unstructured":"Zhao, X. et al. Effects of a prolonged booster interval on neutralization of Omicron variant. N. Engl. J. Med. 386, 894\u2013896 (2022).","journal-title":"N. Engl. J. Med."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01016-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01016-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01016-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T17:05:11Z","timestamp":1731344711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01016-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01016-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.X., Y.A., L.D., and G.F.G. are listed in the patent as the inventors of the RBD-dimer as a coronavirus vaccine. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}